Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

2025 Tandem Meetings

Betty Hamilton, MD: Research Highlights in GVHD

Kristina Maas-Bauer, MD, on ROCK1/2 Inhibition and GVHD

John Magenau, MD, on Alpha-1-Antitrypsin for High-Risk Acute GVHD

Masumi Ueda Oshima, MD, on, a Posttransplant GVHD Prophylaxis Strategy


2025 ASCO GU

Benjamin Maughan, MD, PharmD, on Exercise Therapy for Patients With Advanced Prostate Cancer

Nicholas D. James, PhD, FRCP, MBBS, on an ADT Option: Transdermal Estradiol Patches

Omid Yazdanpanah, MD, on Metastatic Castration-Resistant Prostate Cancer: LuPSMA With or Without ARPIs

Masood Moghul, PhD, on a Mobile Prostate Cancer Clinical Unit: Findings From the Man Van

William Aronson, MD, on a Specialized Diet in Men on Active Surveillance for Prostate Cancer

Karim Fizazi, MD, PhD, on HRR-Deficient mCRPC: Final Overall Survival in TALAPRO-2

Neeraj Agarwal, MD, FASCO, on mCRPC: Talazoparib Plus Enzalutamide as First-Line Treatment

Michael Schweizer, MD: EZH2 Inhibitor Plus Enzalutamide in mCRPC


2025 ASCO GI

Aasma Shaukat, MD, MPH, on A Blood-Based Test for Colorectal Cancer Screening

Thierry André, MD, on First Results From CheckMate 8HW

Susumu Hijioka, MD, on the Phase III STARTER-NET Study in GEP-NET

Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer

Cathy Eng, MD, on the FRESCO-2 Study in Metastatic Colorectal Cancer

Anna Martling, MD, PhD, on the ALASCCA Trial in Colorectal Cancer


2024 SABCS

Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer

Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE

Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis

Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer

Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer

Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer

Jame Abraham, MD, FACP on the Phase III ZEST Trial

Jame Abraham, MD, FACP on the PATINA Trial

Komal Jhaveri, MD, FACP on The Phase III EMBER Trial

Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial


2024 JADPRO Live

Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide

Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer

Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer


Thematic Newsreels

Ovarian Cancer 2024: Year at a Glance, Part 1

Ovarian Cancer 2024: Year-at-a-Glance, Part 2

Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment


2024 ASH Annual Meeting

Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial

Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL

Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia

Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL

Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease

Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease

John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment

John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib

Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL

Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models

Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, on the Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: A Multi-Center Observational Study

Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study

Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes


42nd Annual Chemotherapy Foundation Symposium

Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer

Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer

Tiffany Traina, MD, FASCO, on Advances in the Treatment of HR-Positive Breast Cancer


Lynn Sage Breast Cancer Symposium 2024

Frederick Howard, MD, on the Role of Targeted Therapy and Endocrine Therapy in the Patient With Breast Cancer

Charles E. Geyer, Jr, MD, FACP, on Management of the Patient With HER2-Positive Breast Cancer in 2024

Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer

William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer


Timely Topics

Julie Gralow, MD, FACP, FASCO, on Conserving IV Fluid Supplies During Natural Disasters


ESMO Congress 2024

Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial

Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma

Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE

Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma

Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib

Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma


IBC East 2024

Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates

Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?

Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment


IBC West 2024

Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates

Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer

Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor

Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases


2024 ASCO Annual Meeting

Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib

Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent

Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07

Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab

Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024

Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease

Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data

Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial

Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care

Reshma Jagsi, MD, and Christian F. Singer, MD, MPH, on Early-Stage Breast Cancer: Adding a Vaccine to Neoadjuvant Systemic Therapy

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Clifford A. Hudis, MD: A Message From ASCO’s CEO

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab

Jean-Marc Classe, MD, PhD, on Ovarian Cancer: New Data on Lymphadenectomy From the CARACO Trial

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel

Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care

Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study

Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone

Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases

Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts

Narjust Florez, MD, and Suresh S. Ramalingam, MD, on EGFR-Mutated NSCLC: Update on Osimertinib and Chemoradiotherapy

Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy

Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach

Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study

Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study

Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain

Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax

Amrita Y. Krishnan, MD, and Paula Rodríguez-Otero, MD, PhD, on Multiple Myeloma: Findings From the PERSEUS Trial on a Regimen for Transplant-Eligible Patients

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone

Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study

Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options

Advertisement

Advertisement




Apr
18
Today In Oncology
Renowned Breast Cancer Physician-Scientist to Lead Womens Cancers Program at City of Hope
Poor Agreement Reported Among Diagnostic Tests for Breast Cancer Related Lymphedema
How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC
Advanced Esophageal Cancer NOTCH1 Mutation and Efficacy of Immunotherapy
Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo